Cargando…
Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature
PURPOSE: To evaluate the role of sentinel lymph node (SLN) biopsy in patients with conjuctival melanoma (CjM). STUDY DESIGN: Retrospective observational cohort study and literature review. SUBJECTS: Slovenian patients with CjM are included in the study. METHODS: Prospectively collected data of CjM p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512233/ https://www.ncbi.nlm.nih.gov/pubmed/34633246 http://dx.doi.org/10.1177/10732748211042116 |
_version_ | 1784582942059659264 |
---|---|
author | Peric, Barbara Leiler, Spela Hawlina, Gregor Jancar, Boris Snoj, Marko Perhavec, Andraz |
author_facet | Peric, Barbara Leiler, Spela Hawlina, Gregor Jancar, Boris Snoj, Marko Perhavec, Andraz |
author_sort | Peric, Barbara |
collection | PubMed |
description | PURPOSE: To evaluate the role of sentinel lymph node (SLN) biopsy in patients with conjuctival melanoma (CjM). STUDY DESIGN: Retrospective observational cohort study and literature review. SUBJECTS: Slovenian patients with CjM are included in the study. METHODS: Prospectively collected data of CjM patients treated from June 2005 to December 2016 were retrospectively analyzed. MAIN OUTCOME MEASURES: The numbers of SLN biopsy procedures, positive and false positive SLN, and local and regional relapses have been described together with overall survival. RESULTS: From June 2005 until December 2016, 24 patients with CjM were treated. The median follow-up time was 65.3 months. The mean Breslow thickness was 1.5 mm (sd = 1.8 mm), and ulceration was present in 29% of cases. Altogether, 14/24 (58%) SLN biopsy procedures were performed. SLN was positive in 2/14 (14%) cases. The estimated 5-year overall survival (OS) of the group was 72.5%, with a median survival of 151 months (95% CI 77–224). From January 2013 to January 2020, five (5/140, 3%) authors reported results comparable to our study. CONCLUSION: Our results confirm that CjM is a rare disease with approximately 14% of positive SLN. At the moment, there are no firm conclusions regarding who would benefit most from SLN biopsy or whether or not CLND should be offered. Data from literature emphasize the need for consistent and uniform staging and future multicentric studies. |
format | Online Article Text |
id | pubmed-8512233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-85122332021-10-14 Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature Peric, Barbara Leiler, Spela Hawlina, Gregor Jancar, Boris Snoj, Marko Perhavec, Andraz Cancer Control Original Research Article PURPOSE: To evaluate the role of sentinel lymph node (SLN) biopsy in patients with conjuctival melanoma (CjM). STUDY DESIGN: Retrospective observational cohort study and literature review. SUBJECTS: Slovenian patients with CjM are included in the study. METHODS: Prospectively collected data of CjM patients treated from June 2005 to December 2016 were retrospectively analyzed. MAIN OUTCOME MEASURES: The numbers of SLN biopsy procedures, positive and false positive SLN, and local and regional relapses have been described together with overall survival. RESULTS: From June 2005 until December 2016, 24 patients with CjM were treated. The median follow-up time was 65.3 months. The mean Breslow thickness was 1.5 mm (sd = 1.8 mm), and ulceration was present in 29% of cases. Altogether, 14/24 (58%) SLN biopsy procedures were performed. SLN was positive in 2/14 (14%) cases. The estimated 5-year overall survival (OS) of the group was 72.5%, with a median survival of 151 months (95% CI 77–224). From January 2013 to January 2020, five (5/140, 3%) authors reported results comparable to our study. CONCLUSION: Our results confirm that CjM is a rare disease with approximately 14% of positive SLN. At the moment, there are no firm conclusions regarding who would benefit most from SLN biopsy or whether or not CLND should be offered. Data from literature emphasize the need for consistent and uniform staging and future multicentric studies. SAGE Publications 2021-10-11 /pmc/articles/PMC8512233/ /pubmed/34633246 http://dx.doi.org/10.1177/10732748211042116 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Article Peric, Barbara Leiler, Spela Hawlina, Gregor Jancar, Boris Snoj, Marko Perhavec, Andraz Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature |
title | Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre
Experience and Review of Current Literature |
title_full | Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre
Experience and Review of Current Literature |
title_fullStr | Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre
Experience and Review of Current Literature |
title_full_unstemmed | Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre
Experience and Review of Current Literature |
title_short | Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre
Experience and Review of Current Literature |
title_sort | sentinel node biopsy for conjunctival melanoma; single centre
experience and review of current literature |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512233/ https://www.ncbi.nlm.nih.gov/pubmed/34633246 http://dx.doi.org/10.1177/10732748211042116 |
work_keys_str_mv | AT pericbarbara sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature AT leilerspela sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature AT hawlinagregor sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature AT jancarboris sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature AT snojmarko sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature AT perhavecandraz sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature |